BioLineRx initiates mid-stage study of BL-8040 as stem cell mobilization agent – Seeking Alpha
|
BioLineRx initiates mid-stage study of BL-8040 as stem cell mobilization agent
Seeking Alpha BioLineRx (NASDAQ:BLRX) commences a Phase 2 clinical trial assessing BL-8040 as a single agent to promote stem cell mobilization for allogeneic transplantation. The study will enroll up to 24 donor/recipient pairs, aged 18 – 70. The primary endpoint … BioLineRx Announces Initiation of Phase 2 Trial for BL-8040 as Novel Stem Cell Mobilization Treatment |
